ClinicalTrials.gg

Program

Pan-KRAS Inhibitor BLU-924

In Sanofi’s pipeline, Pan KRAS inhibitor. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Sanofi.

Furthest: phase 2, since Jun 1, 20261 company-led study, 1 open or runningNext primary completion: Sep 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi11 open or runningphase 2since Jun 1, 2026Jun 1, 2026Sep 2029phase 2 · NCT07629960
  • Named in Sanofi’s own pipeline as SAR449336, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 1, 2026First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07629960 · 265 planned · United States, Spain

Ahead

  1. Sep 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07629960

TargetBeta

“Pan KRAS inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable inhibitor of various KRAS mutations, with potential antineoplastic activity. Upon oral administration, pan-KRAS inhibitor BLU-924 targets, binds to and inhibits various forms of KRAS mutations, thereby inhibiting KRAS-dependent signaling. This inhibits the proliferation of …”NCIt, read by Claude
“An orally bioavailable inhibitor of various KRAS mutations, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07629960Carcinoma, Non-Small-Cell Lung · United States, Spain2RecruitingSep 2029265

How it is read

Names in the registry

  • “BLU-924”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.